U.S. Markets closed

Incyte Corporation (INCY)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
121.74-2.60 (-2.09%)
At close: 4:00PM EDT

121.74 0.00 (0.00%)
After hours: 4:50PM EDT

People also watch
VRTXBMRNALXNREGNSGEN
Full screen
Previous Close124.34
Open123.37
Bid121.60 x 100
Ask124.10 x 100
Day's Range121.63 - 125.36
52 Week Range75.52 - 153.15
Volume896,580
Avg. Volume1,593,665
Market Cap25.04B
Beta1.69
PE Ratio (TTM)-216.23
EPS (TTM)-0.56
Earnings DateOct 30, 2017 - Nov 3, 2017
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est148.07
Trade prices are not sourced from all markets
  • See what the IHS Markit Score report has to say about Incyte Corp.
    Markityesterday

    See what the IHS Markit Score report has to say about Incyte Corp.

    The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.

  • Capital Cube2 days ago

    Incyte Corp. – Value Analysis (NASDAQ:INCY) : August 15, 2017

    Categories: Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives Incyte Corp. a score of 53. Our analysis is based on comparing Incyte Corp. with the following peers – Celgene Corporation, Amgen Inc., Ligand Pharmaceuticals Incorporated, Ionis Pharmaceuticals, Inc., Eli Lilly and Company, Pfizer Inc., Geron Corporation, Novartis AG Sponsored ADR, Ardelyx, Inc. and AVEO Pharmaceuticals, Inc. ... Read more (Read more...)

  • Why Gilead Sciences Might Not Make an Oncology Acquisition
    Motley Fool2 days ago

    Why Gilead Sciences Might Not Make an Oncology Acquisition

    Gilead Sciences' CEO hints that buying a biotech with an oncology focus might not happen. Here's what this could mean for the big biotech.